NCT01678898 - Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 6, 2016

Study Completion Date

March 6, 2016

Conditions

Fabry Disease

Interventions

DRUG

PRX-102

Trial Locations (14)

3050

Royal Melbourne Hospital, Victoria Park

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

21205

Johns Hopkins University School of Medicine, Baltimore

22030

O & O Alpan LLC, Fairfax

27710

Duke University Medical Center, Durham

30322

Department of Human Genetics, Emory University School of Medicine, Atlanta

50012

Hospital de Dia Quiron Zaragoza, Zaragoza

52242

University of Iowa Health Clinics, Iowa City

66160

University of Kansas Medical Center, Kansas City

75226

Research Baylor Institute of Metabolic Disease, Dallas

95817

UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics, Sacramento

Unknown

Hematology and Clinical Research Private Institute, Asunción

Clinical Center of Serbia, Belgrade

NW3 2QG

The Royal Free Hospital, London

All Listed Sponsors

collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Protalix

INDUSTRY